Skip to main content
SpringerLink
Log in

Antidementiva

  • Chapter
  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

  • 1653 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Antidementiva im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI et al (2022) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12(10):1290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bartels C, Wagner M, Wolfsgruber S et al (2018) Impact of SSRI Therapy on risk of conversion from mild cognitive impairment to Alzheimer’s dementia in individuals with previous depression. Am J Psychiatry 175(3):232–241

    Article  PubMed  Google Scholar 

  • Battle CE, Abdul-Rahim AH, Shenkin SD et al (2021) Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev 2(2):CD13306

    PubMed  Google Scholar 

  • Bazzari FH, Bazzari AH (2022) BACE1 Inhibitors for Alzheimer’s disease: the past, present and any future? Molecules 27(24):8823

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Christl J, Verhülsdonk S, Pessanha F et al (2019) Association of cerebrospinal fluid S100B protein with core biomarkers and cognitive deficits in prodromal and mild Alzheimer’s disease. J Alzheimers Dis 4:1119–1127

    Article  Google Scholar 

  • Coupland CAC, Hill T, Dening T et al (2019) Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med 179(8):1084–1093

    Article  PubMed  PubMed Central  Google Scholar 

  • DGN, DGPPN (2016) S3-Leitlinie „Demenzen“. https://register.awmf.org/assets/guidelines/038-013l_S3-Demenzen-2016-07.pdf. Zugegriffen: 29. Mai 2023

  • Glans I, Sonestedt E, Nägga K et al (2023) Association between dietary habits in midlife with dementia incidence over a 20-year period. Neurology 100(1):e28–e37

    Article  PubMed  PubMed Central  Google Scholar 

  • Haeberlein BS, Aisen PS, Barkhof F et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 9(2):197–210

    Google Scholar 

  • Honig LS, Barakos J, Dhadda S et al (2023) ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer’s disease. Alzheimers Dement 9(1):e12377

    Article  Google Scholar 

  • Huang LK, Chao SP, Hu CJ (2020) Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 27(1):18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jack CR Jr, Bennett DA, Blennow K et al (2018) Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4):535–562

    Article  PubMed  PubMed Central  Google Scholar 

  • Klein G, Scelsi MA, Barakos J et al (2022) Comparing ARIA-E severity scales and effects of treatment management thresholds. Alzheimers Dement 14(1):e12376

    Google Scholar 

  • Kuller LH, Lopez OL (2021) ENGAGE and EMERGE: truth and consequences? Alzheimers Dement 17(4):692–695

    Article  PubMed  PubMed Central  Google Scholar 

  • Lange-Asschenfeldt C (2013) Vaskuläre Faktoren in der Pathogenese der Alzheimer-Krankheit. Nervenarzt 84(6):732–737

    Article  CAS  PubMed  Google Scholar 

  • Lee J, Howard RS, Schneider LS (2022) The current landscape of prevention trials in dementia. Neurotherapeutics 19(1):228–247

    Article  PubMed  PubMed Central  Google Scholar 

  • Liu YH, Chen Y, Wang QH et al (2022) One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. JAMA Neurol 79(5):509–517

    Article  PubMed  PubMed Central  Google Scholar 

  • Lockery JE, Broder JC, Ryan J et al (2021) A cohort study of anticholinergic medication burden and incident dementia and stroke in older adults. J Gen Intern Med 36(6):1629–1637

    Article  PubMed  PubMed Central  Google Scholar 

  • McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89(1):88–100

    Article  PubMed  PubMed Central  Google Scholar 

  • Mintzer J, Lanctôt KL, Scherer RW et al (2021) Effect of methylphenidate on apathy in patients with Alzheimer disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol 78(11):1324–1332

    Article  PubMed  Google Scholar 

  • Nelson PT, Dickson DW, Trojanowski JQ et al (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142(6):1503–1527

    Article  PubMed  PubMed Central  Google Scholar 

  • Orgeta V, Tabet N, Nilforooshan R, Howard R (2017) Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis. J Alzheimers Dis 58(3):725–733

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ossenkoppele R, Pichet Binette A et al (2022) Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med 28(11):2381–2387

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Palmqvist S, Stomrud E, Cullen N et al (2022) An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease. Alzheimers Dement 19(4):1204–1215

    Article  PubMed  Google Scholar 

  • Pyne JD, Brickman AM (2021) The impact of the COVID-19 pandemic on dementia risk: potential pathways to cognitive decline. Neurodegener Dis 21(1–2):1–23

    Article  CAS  PubMed  Google Scholar 

  • Reiken S, Sittenfeld L, Dridi H et al (2022) Alzheimer’s-like signaling in brains of COVID-19 patients. Alzheimers Dement 18(5):955–965

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Reish NJ, Jamshidi P, Stamm B et al (2023) Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med 388(5):478–479

    Article  PubMed  PubMed Central  Google Scholar 

  • Reyes-Bueno JA, Mena-Vázquez N, Ojea-Ortega T et al (2020) Case fatality of COVID-19 in patients with neurodegenerative dementia. Neurologia 35(9):639–645

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ruthirakuhan M, Ismail Z, Herrmann N et al (2022) Mild behavioral impairment is associated with progression to Alzheimer’s disease: a clinicopathological study. Alzheimers Dement 18(11):2199–2208

    Article  PubMed  Google Scholar 

  • Smith R, Wibom M, Pawlik D et al (2019) Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol 76(3):310–317

    Article  PubMed  Google Scholar 

  • Sondergaard KB, Weeke P, Wissenberg M et al (2017) Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacother 3(2):100–107

    PubMed  Google Scholar 

  • Tan MS, Yu JT, Tan CC et al (2015) Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis 43(2):589–603

    Article  CAS  PubMed  Google Scholar 

  • Tsoi KK, Chan JY, Chan FC et al (2019) Monotherapy is good enough for patients with mild-to-moderate Alzheimer’s disease: a network meta-analysis of 76 randomized controlled trials. Clin Pharmacol Ther 105(1):121–130

    Article  PubMed  Google Scholar 

  • van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388(1):9–21

    Article  PubMed  Google Scholar 

  • Vaz M, Silva V, Monteiro C et al (2022) Role of aducanumab in the treatment of Alzheimer’s disease: challenges and opportunities. Clin Interv Aging 17:797–810

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Düsseldorf/Kaarst, Deutschland

    Prof. Dr. med. Christian Lange-Asschenfeldt

  2. Mainz, Deutschland

    Prof. Dr. med. Otto Benkert

Authors
  1. Prof. Dr. med. Christian Lange-Asschenfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Deutschland

    Otto Benkert

  2. ehemals Universitäts-Klinikum München, München, Deutschland

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lange-Asschenfeldt, C., Benkert, O. (2023). Antidementiva. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-67685-1_6

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-67684-4

  • Online ISBN: 978-3-662-67685-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation